Pfizer to open global network of digital hubs, including in Greece

Pfizer sign
Pfizer expects the Greek facility, the first of six, to become operational in 2020, providing up to 200 jobs. (Tracy Staton)

Pfizer is planning to establish a multinational network of digital research hubs with a focus on artificial intelligence and big data analytics.

Starting with a new facility in the Greek city of Thessaloniki, the Big Pharma hopes to develop tech that can be incorporated into its development pipeline of medicines and vaccines.

“There is a high concentration of digital talent in Greece,” a company spokesperson told FierceMedTech. “Pfizer plans to partner with universities and local innovation incubators to assemble a world-class team in Thessaloniki—one that will help us further advance our purpose: breakthroughs that change patients’ lives.”

Virtual Roundtable

ASCO Explained: Expert predictions and takeaways from the world's biggest cancer meeting

Join FiercePharma for our ASCO pre- and post-show webinar series. We'll bring together a panel of experts to preview what to watch for at ASCO. Cancer experts will highlight closely watched data sets to be unveiled at the virtual meeting--and discuss how they could change prescribing patterns. Following the meeting, we’ll do a post-show wrap up to break down the biggest data that came out over the weekend, as well as the implications they could have for prescribers, patients and drugmakers.

Pfizer expects the facility, the first of six, to become operational in 2020, providing up to 200 jobs. The company has not finalized plans for the remaining locations.

RELATED: Pfizer hires ex-FDA, MD Anderson researcher as clinical oncology lead

The news was first reported by the Athens newspaper Kathimerini, which said Greek Prime Minister Kyriakos Mitsotakis announced the city’s selection during the Thessaloniki International Fair.

Pfizer currently maintains a separate network of "Healthcare Hubs" in different locations across the globe—including New York, London, Berlin, Tel Aviv, Stockholm, Sydney and Toronto—that focus on supporting healthcare and tech startups through the company’s local subsidiaries, plus institutional resources and grants.

Suggested Articles

The FDA named more than two dozen coronavirus antibody tests that should be taken off the market weeks after the agency clamped down on tests.

Inovio CEO J. Joseph Kim is undeterred by short sellers and other detractors who doubt his company can shuttle a COVID-19 DNA vaccine to market.

The machine-learning programs scroll through data to detect hard-to-spot patterns. Yet few have been tested against standard procedures.